Greco Michael V. 4

What Happened

• Michael V. Greco, General Counsel of Veradermics, was granted a derivative equity award (transaction code A) covering 144,401 shares on February 3, 2026. The award shows an acquisition price of $0.00 per share (no cash paid at grant) — this is a compensation grant, not an open-market purchase or sale.

Key Details

• Transaction date: February 3, 2026; Form 4 filed February 5, 2026 (appears timely).
• Transaction type: A = Award/Grant (derivative equity instrument).
• Shares/amount: 144,401 shares underlying the award.
• Price: $0.00 per share at grant (no immediate cash outlay).
• Vesting (per footnote F1): 25% vests on Feb 3, 2027 (one-year cliff), then remaining shares vest in equal monthly installments over the next 36 months, subject to continued service.
• Shares owned after transaction: Not specified in the filing.
• No indication in the filing of a 10b5-1 plan, tax-withholding share surrender, or immediate sale of shares.

Context

• This is a standard executive compensation grant. Because it vests over time and requires continued service, any financial benefit to the insider depends on future vesting and any later exercise/sale; there was no immediate purchase or sale of stock reported.